SAR-428926

N/A

Report date: 2024/02/05 13:50:27

Base Information

Drug NameSAR-428926

Drug Alias NameSAR-428926

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsAnti-LAMP1

TargetsLysosome-associated membrane glycoprotein 1Tubulin

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmarkFranceSpain

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunogen Inc Sanofi

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSanofi

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A